Summary & Overview
CPT 90586: Intravesical Live Vaccine for Bladder Cancer
CPT code 90586 designates intravesical administration of a live vaccine product for the treatment of bladder cancer. This immunotherapeutic procedure is clinically significant as a bladder-preserving therapy option for non-muscle invasive bladder cancer and is commonly performed in outpatient surgical settings. It carries implications for payer coverage, billing practices, and facility workflows nationwide.
Key payers in the national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how this code is used clinically, common payment and billing considerations observed across major payers, and context on where the service is typically delivered. The publication also summarizes available benchmarks and policy updates relevant to intravesical live vaccine administration, and highlights procedural coding nuances that affect claims processing.
This summary is intended to inform billing managers, revenue cycle staff, and clinical administrators about the clinical purpose of CPT code 90586, expected sites of service, and the payer landscape. Data not available in the input is noted where appropriate in detailed sections.
Billing Code Overview
CPT code 90586 represents the administration of a live vaccine product delivered directly into the bladder to treat bladder cancer. This procedure is a form of intravesical immunotherapy that uses a live attenuated organism to stimulate a local immune response against malignant urothelial cells.
-
Service type: Intravesical immunotherapy administration
-
Typical site of service: Hospital outpatient department or ambulatory surgery center, and may also be performed in specialized urology clinics equipped for intravesical therapy
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old male with non-muscle invasive bladder cancer (NMIBC), such as high-grade Ta or T1 transitional cell carcinoma, who presents for intravesical immunotherapy. After transurethral resection of bladder tumor (TURBT) and risk stratification, the urology team schedules intravesical instillation of a live attenuated vaccine product into the bladder to reduce recurrence risk. The procedure is performed in an outpatient urology clinic or ambulatory surgery center. Workflow: pre-procedure evaluation confirming absence of urinary tract infection and active gross hematuria, informed consent for intravesical immunotherapy, bladder catheterization, instillation of the live vaccine agent via the catheter, dwell time monitoring (typically 1–2 hours), removal of catheter if inserted, observation for immediate adverse reactions, and post-procedure discharge instructions including signs of systemic infection or severe urinary symptoms. Typical personnel include a urologist (physician), registered nurse, and ancillary staff. Place of service is commonly an ambulatory surgery center or outpatient clinic procedure room; billing uses the intravesical drug administration code and associated visit orfacility codes as appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard claim submission | Use for routine professional/facility billing when no special circumstances apply |